ESTRO 2024 - Abstract Book

S746

Clinical - CNS

ESTRO 2024

patients. Median time to symptomatic RN was 8 months (range 2-30 months). Local and regional (non-LMM) recurrence was found in 19% and 54% of patients, respectively.

N = 152

Median age at diagnosis

62 (28-83)

Primary

tumor

NSCLC

adenocarcionma

60

(40%)

NSCLC

non-adenocarcinoma

17

(11%)

Breast

cancer

24

(16%)

Colorectal

cancer

11

(7%)

Other

40 (26%)

Number

of

brain

metastases

1 2 3 ≥4

95

(63%)

33

(22%)

15

(10%)

9 (6%)

Location

of

resected

metastasis

Cerebellum

(infratentorial)

40

(26%)

Frontal

lobe

47

(31%)

Occipital

lobe

26

(17%)

Parietal

lobe

21

(14%)

Temporal

lobe

15

(10%)

Basal ganglia

1 (1%)

Fractionation

scheme

3

x

8.5

Gy

67

(44%)

3

x

8

Gy

60

(40%)

1

x

21

Gy

10

(7%)

1

x

18

Gy

9

(6%)

Other

6 (4%)

Extracranial

metastases

at

diagnosis

Yes No

69

(45%)

83 (55%)

Systemic treatment (within 2 months of SRT) Chemtherapy Hormonal therapy Targeted therapy Immunotherapy 37 7 18

(24%)

(5%)

(12%)

16 (11%)

Table 1: Patient characteristics